Neola Medical takes an important step forward in advancing neonatal care. After years of development, the company has received approval to initiate its first clinical study on preterm born babies—a key step in evaluating its continiuos lung monitoring device, Neola®, for this vulnerable patient group. In an interview with Life Science Sweden, CEO Hanna Sjöström discusses the significance of this milestone, what it means for the company, and how it supports Neola Medical’s strategy for entering the U.S. market, where Neola Medical sees significant potential for growth and impact in neonatal care.
Read the full interview here: Life Science Sweden interview with CEO Hanna Sjöström